Welcome to our dedicated page for TEVA PHARMACEUTICAL INDUSTRIES SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TEVA PHARMACEUTICAL INDUSTRIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TEVA PHARMACEUTICAL INDUSTRIES's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries Ltd. (TEVA) reported a material modification to the rights of its security holders by amending its deposit agreement and updating the form of American depositary receipt in connection with terminating its American depositary share (ADS) program. Each ADS represents one ordinary share, par value NIS 0.10 per share.
The amendment establishes a mandatory exchange under which each ADS will be exchanged for one ordinary share, and all outstanding ADSs will be cancelled in exchange for an equal number of economically equivalent ordinary shares listed on the New York Stock Exchange. The termination of the ADS program is expected to occur at the open of business (New York time) on September 14, 2026.
TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD) reported insider transactions by Chief Accounting Officer Amir Weiss on 2026-08-21. Weiss exercised stock options covering 2,500 Ordinary Shares at an exercise price of $19.16 per share and then sold a total of 9,445 Ordinary Shares in open-market transactions, including 6,945 shares at a weighted average price of $37.61 (in a range of $31.62 to $37.61) and 2,500 shares at $37.63 per share. The options, which expire on March 2, 2028, were originally granted in 2018 and vested in tranches from 2019 to 2022. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) director Ronit Satchi-Fainaro reported selling 415 Ordinary Shares on August 21, 2026 at a price of $37.25 per share in an open-market or private transaction. Following this sale, the director directly holds 111,986 Ordinary Shares, which may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported that executive Evan Lippman, EVP, Business Development, sold 18,600 Ordinary Shares on August 17, 2026. The shares, which may be represented by American Depositary Shares on a one-for-one basis, were sold at a weighted average price of $36.5748, with individual trades between $36.57 and $36.61. After this sale, Lippman directly holds 25,591 Ordinary Shares. The transaction was effected under a Rule 10b5-1 trading plan adopted on May 16, 2026, indicating it followed a pre-established trading schedule.
Tal Zvi Zaks, a director of TEVA PHARMACEUTICAL INDUSTRIES LTD, reported a sale of 17 Ordinary Shares on 2026-08-05 in a sale in open market or private transaction at $34.8655 per share. Following this transaction, the director directly holds 73,247 Ordinary Shares, which may be represented by American Depositary Shares. The Rule 10b5-1 trading-plan checkbox was not selected.
Teva Pharmaceutical Industries executive Placid Jover, Executive Vice President and Chief Human Resources Officer, converted 12,827 restricted share units into the same number of ordinary shares on August 3, 2026, then sold all 12,827 shares, including shares to cover tax-withholding obligations, at a weighted average $34.8757 under a Rule 10b5-1 trading plan, leaving 25,657 restricted share units outstanding from his August 2024 grant.
Teva Pharmaceutical Industries executive Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer, exercised 52,744 restricted share units into ordinary shares on August 3, 2026. He then sold 25,578 ordinary shares at a weighted average of $34.8757 per share under a Rule 10b5-1 trading plan to cover tax withholding obligations related to the RSU vesting.
Teva Pharmaceutical Industries Limited has a holder planning to sell ordinary shares under a resale notice. The plan covers 25,578 ordinary shares to be sold through Citigroup Global Markets, Inc. on or after August 3, 2026, with an indicated aggregate market value of $892,050.65. The shares relate to a Restricted Share Unit Award that vested on August 1, 2022 in respect of services rendered.
Teva Pharmaceutical Industries Limited filed a notice of proposed sale of ordinary shares under Rule 144. The filer plans to sell up to 12,827 ordinary shares through Citigroup Global Markets, Inc. on the NYSE, with an approximate sale date of 08/03/2026.
The shares relate to a Restricted Share Unit Award that vested on 08/01/2024 as compensation for services rendered. The filing lists an aggregate market value of $447,350.60 for the shares and references 1,165,296,084 ordinary shares outstanding as context.